<div id="readability-page-1">New insider activity at Guardant Health ( (GH) ) has taken place on January 22, 2026.<h3>Claim 50% Off TipRanks Premium</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li></ul> Guardant Health’s Chief People Officer, Terilyn J. Monroe, recently executed a significant stock transaction, selling 8,571 shares of Guardant Health stock in a move valued at $977,839. This insider sale highlights notable activity within the company’s executive ranks and may draw attention from investors tracking leadership confidence and ownership changes. Recent Updates on GH stock Over the last 24 hours, Guardant Health has seen a cluster of positive fundamental and regulatory developments that underpin several analyst price target revisions, alongside continued strong trading momentum. The company reported that 2025 was a “breakout year,” with about 33% total revenue growth driven by robust expansion in both oncology testing and rapid adoption of its Shield colorectal cancer screening test, including a sharp year-over-year jump in quarterly Shield volumes and an expansion of Shield into multi‑cancer detection findings; this reinforced expectations for sustained volume growth despite the company remaining cash‑flow negative. In parallel, Guardant announced a key FDA approval for Guardant360 CDx as the first companion diagnostic in colorectal cancer to identify BRAF V600E‑mutant metastatic patients eligible for Braftovi plus cetuximab and chemotherapy, supported by Phase 3 BREAKWATER data, which strengthens its clinical and commercial positioning in precision oncology. Against this backdrop, multiple firms raised their price targets: Stifel cited expectations for a solid 2026 driven by continued test volume and pricing growth plus upcoming publication and reimbursement catalysts; TD Cowen’s adjustment came as part of a sector-wide Q4 preview in which it highlighted solid expected results and fundamentals for diagnostics and a constructive 2026 outlook; and Mizuho’s increase reflected updated models across its medical devices and diagnostics coverage. Collectively, these moves suggest that analysts are increasingly factoring in Guardant’s accelerating top‑line trajectory, expanding indications, and supportive industry fundamentals, while remaining mindful of the company’s ongoing profitability and cash‑flow challenges. Spark’s Take on GH Stock According to Spark, TipRanks’ AI Analyst, GH is a Neutral. The score is held back primarily by weak financial stability (negative equity, heavy losses, and ongoing cash burn). Offsetting this, price action and momentum are strong, and the latest earnings call/guidance pointed to accelerating revenue growth and improving gross margins. Valuation remains difficult to support due to negative earnings and no dividend yield. To see Spark’s full report on GH stock, click here. More about Guardant Health YTD Price Performance: 13.32% Average Trading Volume: 2,528,678 Technical Sentiment Signal: Buy Current Market Cap: $14.86B</div>

Guardant Health's Chief People Officer, Terilyn J. Monroe, sold 8,571 shares valued at $977,839, indicating notable insider activity. The company reported a 33% revenue growth in 2025, driven by oncology testing and the Shield colorectal cancer screening test. Recent FDA approval for Guardant360 CDx enhances its market position. Analysts have raised price targets, reflecting confidence in growth despite ongoing cash-flow challenges. TipRanks’ AI Analyst rates GH as Neutral, citing weak financial stability but strong price momentum and improving revenue growth.

Tip Ranks

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

iShares Genomics Immunology and Healthcare ETF

Health Care Select Sector SPDR

iShares US Medical Devices

iShares US Healthcare Providers

ALPS Medical Breakthrough

Guardant Health

Direxion S&P Biotech Bear 3X

SPDR S&P Biotech

VanEck Biotech ETF

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Top Guardant Health Executive Makes Eye-Catching Stock Move